Here are relevant reports on : antiviral-drugs-market
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The North America human microbiome market is expected to grow from USD 0.78 billion in 2025 to USD 4.15 billion in 2031, at a compound annual growth rate (CAGR) of 32.2% during the forecast period. The Key Players Seres Therapeutics (US), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Resbiotic (US), Infinant Health Inc. (US), and ExeGi Pharma (US).
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029
The global poultry medicine/pharmaceuticals market, valued at US$4.73 billion in 2023, stood at US$5.01 billion in 2024 and is projected to advance at a resilient CAGR of 5.9% from 2024 to 2029, culminating in a forecasted valuation of US$6.68 billion by the end of the period. The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Veterinary Pharmaceuticals Market by Product (Drugs, Vaccines, Medicatives feed additives), Animal Type (Production, Companion), Route of Administration (Oral, Parenteral), Distribution Channel (Veterinary Hospitals, Clinics), Indication (Infectious, Dermatology, Pain) and Region - Global Forecast to 2027
The global veterinary pharmaceuticals market size is projected to reach USD 39.0 billion by 2027 from USD 27.5 billion in 2022, at a CAGR of 7.5% during the forecast period. Market is driven by factors such as growing livestock population, rise in pet ownership, rising meat & diary consumption, incrementing number of infectious diseases among animals, mandatory animal vaccinations. On the other hand, rising threat of antibiotic resistance, poor veterinary healthcare infrastructure is expected to limit market growth to a certain extent in the coming years.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Human Insulin Market By Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Global Forecast to 2020
The global human insulin market size is projected to grow at a CAGR of 8.1%. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of this market.
- Published: December 2015
- Price: $ 4950
- TOC Available:
-
Renal Cancer Drugs Market by therapy (targeted therapy, chemotherapy, and immunotherapy), drug class (anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors), indication (renal cell carcinoma, urothelial carcinoma, and others), distribution channel (hospitals, specialty & retail pharmacies and others), and region (North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa) – global forecasts to 2027
The renal cancer drugs market is projected to reach USD 8 billion by 2027 from USD 6 billion in 2022, at a CAGR of 6% during the forecast period.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Patient Registry Software Market by Disease (Diabetes, Cancer, Rare, Asthma, Kidney), Product (Drugs, Device), Use Case (Population Health, Research), End User ((Profit: Pharma, Payer, Hospital), (Non-Profit: Govt)) & Region - Global Forecast to 2030
The global patient registry software market, valued at US$2.06 billion in 2024, stood at US$2.25 billion in 2025 and is projected to advance at a resilient CAGR of 9.8% from 2025 to 2030, culminating in a forecasted valuation of US$3.61 billion by the end of the period. The robust growth in registry software solutions is driven by a focus on patient-centric care and value-based healthcare delivery. Due to their flexibility and cost-effectiveness, the demand for public databases and cloud-based models is increasing.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Grignard Reagents Market by Product Type (Alkyl Grignard Reagents, Vinyl Grignard Reagents, Aryl Grignard Reagents), Application (APIs & Drugs, Agrochemicals, Polymer Synthesis & Functionalization), End-use Industry (Pharmaceutical & Biotechnology, Agriculture, Chemical, Flavors & Fragrances, Research), and Region - Global Forecast to 2030
The grignard reagents market is expected to grow from USD 5.07 billion in 2025 to USD 6.67 billion in 2030, at a CAGR of 5.6% during the forecast period. Prominent companies in this market include Merck KGaA (Germany), Albemarle Corporation (US), WeylChem International GmbH (Germany), HOKKO CHEMICAL INDUSTRY CO., LTD. (Japan), CHEMIUM srl (Belgium), FAR Chemical (US), PMC Group, Inc (US), Boulder Scientific Group (US), Neogen Chemicals Ltd (India), Tokyo Chemical Industry (India) Pvt. Ltd. (India), Optima Chem (US), Shaoxing Shangyu Hualun Chemical Co., Ltd. (China), Nanjing Freehoo Chemical Technology Co., Ltd (China), Chemische Fabrik Karl Bucher GmbH (Germany), and Jiangsu Changjili New Energy Technology Co., Ltd. (China).
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024
The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024, at a CAGR of 6.8%. Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
- Published: May 2019
- Price: $ 4950
- TOC Available:
-
US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Global Forecast to 2022
The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%. The US anticoagulation therapy market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics. C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the US anticoagulation therapy market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.
- Published: November 2017
- Price: $ 4950
- TOC Available:
-
Peptide and Anticoagulant Drugs Market by Type (Hormonal (Insulin, Teriparatide, Calcitonin), Antibiotic (Colistin, Cycloserine), Low molecular weight heparin (Enoxaparin Sodium, Heparin Sodium), Application (Diabetes, Cancer) - Global Forecast to 2022
The Indian peptide drugs market is expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and is expected to register a CAGR of 15.0%. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market. The Indian anticoagulant drugs market is expected to reach USD 170.2 Million in 2022 from USD 127.8 Million in 2016 and is expected to register a CAGR of 4.9%. Factors such as incidence of coagulation disorders and government support for pharmaceutical companies are contributing to the growth of this market. Some of the major players operating in the Indian anticoagulant drugs market are Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India).
- Published: August 2017
- Price: $ 7150
- TOC Available:
Records 31 to 40 of 50
